We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+2%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$339M
AUM Growth
+$36.2M
Cap. Flow
+$31.5M
Cap. Flow %
9.29%
Top 10 Hldgs %
40.44%
Holding
118
New
22
Increased
42
Reduced
29
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.37M
2
LH icon
Labcorp
LH
+$7.04M
3
JNJ icon
Johnson & Johnson
JNJ
+$6.49M
4
BDX icon
Becton Dickinson
BDX
+$5.83M
5
UHS icon
Universal Health Services
UHS
+$5.72M

Top Sells

Rank Stock Value
1
AMSG
Amsurg Corp
AMSG
+$5.97M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$5.94M
3
HOLX
Hologic
HOLX
+$5.76M
4
CYH icon
Community Health Systems
CYH
+$4.33M
5
CAH icon
Cardinal Health
CAH
+$4.22M

Sector Composition

Rank Sector Weight
1 Healthcare 89.84%
2 Financials 0.85%
3 Technology 0.78%
4 Real Estate 0.25%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
76
DELISTED
Alpine Immune Sciences Inc
ALPN
$704K 0.21%
+11,625
New +$692K
CTLT
77
DELISTED
CATALENT, INC.
CTLT
$678K 0.2%
+23,100
New +$697K
ALGN icon
78
Align Technology
ALGN
$12.1B
$671K 0.2%
10,700
+6,900
+182% +$408K
TRNX
79
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$661K 0.2%
26,468
+1,900
+8% +$49.4K
ACAD icon
80
Acadia Pharmaceuticals
ACAD
$4.43B
$628K 0.19%
+15,000
New +$581K
BLUE
81
DELISTED
bluebird bio
BLUE
$589K 0.17%
270
-332
-55% -$676K
PTX
82
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$583K 0.17%
+9,850
New +$695K
STRM
83
DELISTED
Streamline Health Solutions
STRM
$559K 0.17%
+13,309
New +$503K
GNMK
84
DELISTED
GenMark Diagnostics, Inc
GNMK
$535K 0.16%
+59,070
New +$596K
THOR
85
DELISTED
THORATEC CORPORATION
THOR
$508K 0.15%
+11,400
New +$499K
XENT
86
DELISTED
Intersect ENT, Inc
XENT
$491K 0.14%
17,135
-45,865
-73% -$1.2M
CLDX icon
87
Celldex Therapeutics
CLDX
$2.99B
$469K 0.14%
1,240
-2,493
-67% -$990K
PODD icon
88
Insulet
PODD
$11.5B
$438K 0.13%
14,150
-71,950
-84% -$2.12M
PBYI icon
89
Puma Biotechnology
PBYI
$404M
$432K 0.13%
3,700
+1,400
+61% +$254K
OCR
90
DELISTED
OMNICARE INC
OCR
$391K 0.12%
4,145
-21,800
-84% -$1.94M
VAR
91
DELISTED
Varian Medical Systems, Inc.
VAR
$366K 0.11%
+4,949
New +$387K
ACOR
92
DELISTED
Acorda Therapeutics
ACOR
$320K 0.09%
80
+2
+3% +$7.73K
TVTY
93
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$240K 0.07%
+20,000
New +$332K
ARWR icon
94
Arrowhead Research
ARWR
$11.9B
– –
-28,900
Closed -$196K
BRKR icon
95
Bruker
BRKR
$9.57B
– –
-25,000
Closed -$462K
CAH icon
96
Cardinal Health
CAH
$53.9B
– –
-46,800
Closed -$4.22M
CYH icon
97
Community Health Systems
CYH
$393M
– –
-100,128
Closed -$4.33M
EHC icon
98
Encompass Health
EHC
$11B
– –
-88,479
Closed -$3.12M
ENTA icon
99
Enanta Pharmaceuticals
ENTA
$366M
– –
-131,100
Closed -$4.01M
HOLX
100
DELISTED
Hologic
HOLX
– –
-174,540
Closed -$5.76M
1 2 3
4
5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Endurant Capital Management held 118 positions worth $339M, up 12% from $303M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Endurant Capital Management deployed $31.5M of net new capital in Q2 2015, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was EndoChoice Holdings, Inc.: 328,501 shares worth $5.37M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Amsurg Corp, an estimated $5.97M trimmed.

  • Endurant Capital Management's largest Q2 2015 buy was EndoChoice Holdings, Inc.: 328,501 shares worth $5.37M.
  • Endurant Capital Management added most to Merck in Q2 2015, an estimated $9.37M increase.
  • Endurant Capital Management's biggest Q2 2015 reduction was Amsurg Corp, cutting an estimated $5.97M.
  • Endurant Capital Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $5.94M.
  • Endurant Capital Management's ten largest holdings make up 40% of its $339M portfolio in Q2 2015.
  • Endurant Capital Management opened 22 new positions and closed 25 in Q2 2015.
  • Endurant Capital Management's portfolio value rose 12% quarter-over-quarter to $339M.

Based on Endurant Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.